Granulocyte Colony-Stimulating Factor is named as a drug or biological intervention in 3 clinical trials in our USA, China and UK trial registers, 3 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (1), Kura Oncology, Inc. (1) and Shanxi Bethune Hospital (1). Registered phases: Phase 2/3, Phase 1 and Phase 3. Conditions studied include DLBCL; Diffuse Large B-Cell Lymphoma; AML.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05726110 | Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia (ClinicalTrials.gov ↗) Relapsed or Refractory Acute Myeloid Leukemia |
Phase 3 | Recruiting |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (ClinicalTrials.gov ↗) DLBCL, Diffuse Large B-Cell Lymphoma |
Phase 2/3 | Recruiting |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (ClinicalTrials.gov ↗) AML, AML With Mutated NPM1, Hematologic Malignancy |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| DLBCL | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| AML | 1 |
| AML With Mutated NPM1 | 1 |
| Hematologic Malignancy | 1 |
| KMT2Ar | 1 |
| Relapsed or Refractory Acute Myeloid Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 1 |
| Kura Oncology, Inc. | 1 |
| Shanxi Bethune Hospital | 1 |
| Register | Granulocyte Colony-Stimulating Factor trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Granulocyte Colony-Stimulating Factor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Granulocyte Colony-Stimulating Factor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.